<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Glatiramer acetate</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Glatiramer_acetate">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Glatiramer acetate</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Glatiramer acetate</b> (also known as <b>Copolymer 1</b>, <b>Cop-1</b>, or <b>Copaxone</b>) is an immunomodulator medication currently used to treat multiple sclerosis. Glatiramer acetate is approved in the United States to reduce the frequency of relapses, but not for reducing the progression of disability. Observational studies, but not randomized controlled trials, suggest that it may reduce progression of disability. While a conclusive diagnosis of multiple sclerosis requires a history of two or more episodes of symptoms and signs, glatiramer acetate is approved to treat a first episode anticipating a diagnosis. It is also used to treat relapsing-remitting multiple sclerosis. It is administered by subcutaneous injection.</p>

<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Glatiramer acetate</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline class="mw-default-size"><img src="../I/m/Glatiramer_acetate.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Glatiramer_acetate.svg.png" data-file-width="802" data-file-height="364" data-file-type="drawing" height="100" width="220"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Copaxone,<span class="mw-ref" id="cite_ref-1"><a href="#cite_note-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> Glatopa<span class="mw-ref" id="cite_ref-2"><a href="#cite_note-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/glatiramer_acetate.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/glatiramer_acetate.html'" tppabs="https://www.drugs.com/monograph/glatiramer_acetate.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span><span>FDA:<span>&nbsp;</span><a href="javascript:if(confirm('https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=glatiramer&SearchType=BasicSearch  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=glatiramer&SearchType=BasicSearch'" tppabs="https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchTerm=glatiramer&SearchType=BasicSearch" class="external text external">glatiramer</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>B1<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>B (No risk in non-human studies)<span> </span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>Subcutaneous injection</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L03AX13<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L03AX13  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L03AX13'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L03AX13" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=147245-92-9  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=147245-92-9'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=147245-92-9" class="external text external">147245-92-9</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/3081884  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/3081884'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/3081884" class="external text external">3081884</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB05259  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB05259'" tppabs="https://www.drugbank.ca/drugs/DB05259" class="external text external">DB05259</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=5M691HL4BO  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=5M691HL4BO'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=5M691HL4BO" class="external text external">5M691HL4BO</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201507  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201507'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL1201507" class="external text external">ChEMBL1201507</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID30163637  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID30163637'" tppabs="https://comptox.epa.gov/dashboard/DTXSID30163637" class="external text external">DTXSID30163637</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.248.824  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.248.824'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.248.824" class="external text external">100.248.824</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>25</sub><span>H</span><sub>45</sub><span>N</span><sub>5</sub><span>O</span><sub>13</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">623.657</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><sup><figure-inline><span><img src="../I/m/X_mark.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/X_mark.svg.png" data-file-width="525" data-file-height="600" data-file-type="drawing" height="8" width="7"></span></figure-inline><span style="display:none">N</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup><span>&nbsp;</span>(what is this?)</span><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=387696338&page2=Glatiramer+acetate  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=387696338&page2=Glatiramer+acetate'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=387696338&page2=Glatiramer+acetate" class="external text external">(verify)</a></span></span></td></tr></tbody></table>
<p>It is a mixture of random-sized peptides that are composed of the four amino acids found in myelin basic protein, namely <a href="Glutamic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Glutamic_acid" title="Glutamic acid">glutamic acid</a>, <a href="Lysine.htm" tppabs="https://ptable.com/wiki/compounds/A/Lysine" title="Lysine">lysine</a>, <a href="Alanine.htm" tppabs="https://ptable.com/wiki/compounds/A/Alanine" title="Alanine">alanine</a>, and <a href="Tyrosine.htm" tppabs="https://ptable.com/wiki/compounds/A/Tyrosine" title="Tyrosine">tyrosine</a>. Myelin basic protein is the antigen in the myelin sheaths of the neurons that stimulates an autoimmune reaction in people with MS, so the peptide may work as a decoy for the attacking immune cells.</p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    
<p>A 2010 Cochrane review concluded that glatiramer acetate had partial efficacy in "relapse-related clinical outcomes" but no effect on progression of the disease.<span class="mw-ref" id="cite_ref-2010cochrane_3-0"><a href="#cite_note-2010cochrane-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> As a result, it is approved by the FDA for reducing the frequency of relapses, but not for reducing the progression of disability.<span class="mw-ref" id="cite_ref-4"><a href="#cite_note-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>

<p>A 15-year followup of the original trial compared patients who continued with glatiramer to patients who dropped out of the trial. Patients with glatiramer had reduced relapse rates, and decreased disability progression and transition to secondary progressive MS, compared to patients who did not continue glatiramer. However, the two groups were not necessarily comparable, as it was no longer a randomized trial. There were no long-term safety issues.<span class="mw-ref" id="cite_ref-Ford2010_5-0"><a href="#cite_note-Ford2010-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    
<div class="thumb tright"><div class="thumbinner" style="width:222px"><img src="../I/m/Copaxone_Injection_Site_Reaction.JPG" tppabs="https://ptable.com/wiki/compounds/I/m/Copaxone_Injection_Site_Reaction.JPG" data-file-width="315" data-file-height="456" data-file-type="bitmap" height="318" width="220"><div class="thumbcaption" style="text-align: left">An injection site reaction on the upper left arm</div></div></div>
<p>Side effects may include a lump at the injection site (injection site reaction) in approximately 30% of users, and aches, fever, chills (flu-like symptoms) in approximately 10% of users.<span class="mw-ref" id="cite_ref-6"><a href="#cite_note-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span> Side effect symptoms are generally mild in nature. A reaction that involves flushing, shortness in breath, anxiety and rapid heartbeat has been reported soon after injection in up to 5% of patients (usually after injecting directly into a vein). These side effects subside within thirty minutes. Over time, a visible dent at the injection site can occur due to the local destruction of fat tissue, known as lipoatrophy, that may develop.</p>

<p>More serious side effects have been reported for glatiramer acetate, according to the FDA's prescribing label, these include serious side effects to the cardiovascular, digestive (including the liver), hematopoietic, lymphatic, musculoskeletal, nervous, respiratory, and urogenital systems as well as special senses (in particular the eyes). Metabolic and nutritional disorders have also been reported; however a link between glatiramer acetate and these adverse effects has not been established.<span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span></p>

<p>It may also cause Jessner lymphocytic infiltrate.<span class="mw-ref" id="cite_ref-8"><a href="#cite_note-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanism_of_action">Mechanism of action</h2></summary>
    
<p>Glatiramer acetate is a random polymer (average molecular mass 6.4<span>&nbsp;</span>kD) composed of four amino acids found in myelin basic protein. The mechanism of action for glatiramer acetate is not fully elucidated. It is thought to act by modifying immune processes that are currently believed to be responsible for the pathogenesis of MS. Administration of glatiramer acetate shifts the population of T cells from proinflammatory Th1 T-cells to regulatory Th2 T-cells that suppress the inflammatory response.<span class="mw-ref" id="cite_ref-9"><a href="#cite_note-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> Given its resemblance to myelin basic protein, glatiramer acetate may act as a decoy, diverting an autoimmune response against myelin. This hypothesis is supported by findings of studies that have been carried out to explore the pathogenesis of experimental autoimmune encephalomyelitis (EAE), a condition induced in several animal species through immunization against central nervous system derived material containing myelin and often used as an experimental animal model of MS. Studies in animals and in vitro systems suggest that upon its administration, glatiramer acetate-specific regulatory T cells (Tregs) are induced and activated in the periphery, inhibiting the inflammatory reaction to myelin basic protein.<span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span></p>

<p>The integrity of the blood-brain barrier, however, is not appreciably affected by glatiramer acetate, at least not in the early stages of treatment. Glatiramer acetate has been shown in clinical trials to reduce the number and severity of multiple sclerosis exacerbations.<span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    
<p>Glatiramer acetate was originally discovered by Michael Sela, Ruth Arnon and <span class="new">Dvora Teitelbaum</span> at the Weizmann Institute of Science in Rehovot, Israel. Three main clinical trials followed to demonstrate safety and efficacy: The first trial was performed in a single center, double-blind, placebo controlled trial and included 50 patients.<span class="mw-ref" id="cite_ref-12"><a href="#cite_note-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span>
The second trial was a two-year, multi-center, randomized, double-blind, placebo controlled trial and involved 251 patients.<span class="mw-ref" id="cite_ref-13"><a href="#cite_note-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span> The third trial was a double-blind MRI study  involving participation of 239 patients.<span class="mw-ref" id="cite_ref-14"><a href="#cite_note-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Society_and_culture">Society and culture</h2></summary>
    

    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Marketing">Marketing</h3></summary>
    
<p>Glatiramer acetate has been approved for marketing in numerous countries worldwide, including the United States, Israel, Canada and 24 European Union countries.<span class="mw-ref" id="cite_ref-15"><a href="#cite_note-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-16"><a href="#cite_note-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> Approval in the U.S. was obtained in 1997.<span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span> Glatiramer acetate was approved for marketing in the U.K. in August 2000, and launched in December.<span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span> This first approval in a major European market led to approval across the European Union under the mutual recognition procedure.
Iran is proceeding with domestic manufacture of glatiramer acetate.<span class="mw-ref" id="cite_ref-19"><a href="#cite_note-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span><span class="mw-ref" id="cite_ref-20"><a href="#cite_note-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Patent_status">Patent status</h3></summary>
    

<p>Novartis subsidiary Sandoz has marketed Glatopa since 2015, a generic version of the original Teva 20<span>&nbsp;</span>mg formulation that requires daily injection.<span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></p>

<p>Teva developed a long-acting 40<span>&nbsp;</span>mg formulation, marketed since 2015, which reduced required injections to three per week.<span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span> In October 2017, the FDA approved a generic version, which is manufactured in India by Natco Pharma, and imported and sold by Dutch firm Mylan.<span class="mw-ref" id="cite_ref-23"><a href="#cite_note-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span><span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span>  In February 2018, Sandoz received FDA approval for their generic version.<span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span> In parallel with the development and approval processes, the generic competitors have disputed Teva's newer patents, any of which if upheld, would prevent marketing of long-acting generics.<span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span></p>

<p>While the patent on the chemical drug expired in 2015,<span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span> Teva obtained new US patents covering pharmaceutical formulations for long-acting delivery.<span class="mw-ref" id="cite_ref-28"><a href="#cite_note-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span>  Litigation from industry competitors in 2016-2017 resulted in the new patents being judged invalid.<span class="mw-ref" id="cite_ref-29"><a href="#cite_note-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span><span class="mw-ref" id="cite_ref-30"><a href="#cite_note-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span>  In October 2018, the U.S. Court of Appeals for the Federal Circuit upheld the patent invalidation for obviousness.<span class="mw-ref" id="cite_ref-31"><a href="#cite_note-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span><span class="mw-ref" id="cite_ref-32"><a href="#cite_note-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span>  The case reflects the larger controversy over evergreening of generic drugs.</p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="See_also">See also</h2></summary>
    
<ul><li><i>Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.</i></li></ul>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist columns references-column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;">
<ol class="mw-references references"><li id="cite_note-1"> <span id="mw-reference-text-cite_note-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.copaxone.com/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.copaxone.com/'" tppabs="https://www.copaxone.com/" class="external text external">"Copaxone® (official Web site)"</a>.</cite></span></li><li id="cite_note-2"> <span id="mw-reference-text-cite_note-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.momentapharma.com/products/glatopa.php  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.momentapharma.com/products/glatopa.php'" tppabs="http://www.momentapharma.com/products/glatopa.php" class="external text external">"Glatopa® (official Web site)"</a>.</cite></span></li><li id="cite_note-2010cochrane-3"> <span id="mw-reference-text-cite_note-2010cochrane-3" class="mw-reference-text"><cite id="CITEREFLa_MantiaMunariLovati2010" class="citation journal cs1">La Mantia L, Munari LM, Lovati R (May 2010). "Glatiramer acetate for multiple sclerosis". <i>The Cochrane Database of Systematic Reviews</i>. <b>5</b> (5): CD004678. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2F14651858.CD004678.pub2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2F14651858.CD004678.pub2'" tppabs="https://doi.org/10.1002%2F14651858.CD004678.pub2" class="external text external">10.1002/14651858.CD004678.pub2</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20464733  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20464733'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20464733" class="external text external">20464733</a>.</cite></span></li><li id="cite_note-4"> <span id="mw-reference-text-cite_note-4" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020622s057lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020622s057lbl.pdf'" tppabs="http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020622s057lbl.pdf" class="external text external">"COPAXONE (glatiramer acetate) solution for subcutaneous injection: Full Prescribing Information (Package insert)"</a> <span class="cs1-format">(PDF)</span>. United States Food and Drug Administration. <q>Label approved on 02/27/2009 (PDF) for COPAXONE, NDA no. 020622</q></cite></span></li><li id="cite_note-Ford2010-5"> <span id="mw-reference-text-cite_note-Ford2010-5" class="mw-reference-text"><cite id="CITEREFFordGoodmanJohnsonKachuck2010" class="citation journal cs1">Ford C, Goodman AD, Johnson K, Kachuck N, Lindsey JW, Lisak R,  et al. (March 2010). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850588  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850588'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850588" class="external text external">"Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate"</a>. <i>Multiple Sclerosis</i>. <b>16</b> (3): 342–50. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1177%2F1352458509358088  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1177%2F1352458509358088'" tppabs="https://doi.org/10.1177%2F1352458509358088" class="external text external">10.1177/1352458509358088</a></span>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850588  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850588'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850588" class="external text external">2850588</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20106943  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20106943'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20106943" class="external text external">20106943</a>.</cite></span></li><li id="cite_note-6"> <span id="mw-reference-text-cite_note-6" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.mediguard.org/medication/view/copaxone  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.mediguard.org/medication/view/copaxone'" tppabs="https://www.mediguard.org/medication/view/copaxone" class="external text external">"Copaxone"</a>. MediGuard.</cite></span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://web.archive.org/web/20030425230757/https://www.fda.gov/cder/foi/label/2001/20622s15lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20030425230757/https://www.fda.gov/cder/foi/label/2001/20622s15lbl.pdf'" tppabs="https://web.archive.org/web/20030425230757/https://www.fda.gov/cder/foi/label/2001/20622s15lbl.pdf" class="external text external">"COPAXONE (glatiramer acetate for injection)"</a> <span class="cs1-format">(PDF)</span>. Food and Drug Administration. Archived from <a href="javascript:if(confirm('https://www.fda.gov/cder/foi/label/2001/20622s15lbl.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/cder/foi/label/2001/20622s15lbl.pdf'" tppabs="https://www.fda.gov/cder/foi/label/2001/20622s15lbl.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 25 April 2003. <q>NDA 20-622/S-015/S-015</q></cite></span></li><li id="cite_note-8"> <span id="mw-reference-text-cite_note-8" class="mw-reference-text"><cite id="CITEREFKrafchik2011" class="citation book cs1">Krafchik BR (2011). <a href="javascript:if(confirm('https://books.google.ca/books?id=tAlGLYplkacC&pg=PA1022  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://books.google.ca/books?id=tAlGLYplkacC&pg=PA1022'" tppabs="https://books.google.ca/books?id=tAlGLYplkacC&pg=PA1022" class="external text external">"Reaction Patterns"</a>.  In Schachner LA, Hansen RC (eds.). <i>Pediatric Dermatology</i>. Elsevier Health Sciences. p.<span>&nbsp;</span>1022. ISBN<span>&nbsp;</span><bdi>978-0-7234-3665-2</bdi>.</cite></span></li><li id="cite_note-9"> <span id="mw-reference-text-cite_note-9" class="mw-reference-text"><cite id="CITEREFArnonSela1999" class="citation journal cs1">Arnon R, Sela M (1999). <a href="javascript:if(confirm('https://web.archive.org/web/20030907080548/http://www.weizmann.ac.il/ICS/booklet/1/pdf/copaxon.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://web.archive.org/web/20030907080548/http://www.weizmann.ac.il/ICS/booklet/1/pdf/copaxon.pdf'" tppabs="https://web.archive.org/web/20030907080548/http://www.weizmann.ac.il/ICS/booklet/1/pdf/copaxon.pdf" class="external text external">"The chemistry of the Copaxone drug"</a> <span class="cs1-format">(PDF)</span>. <i>Chem. Israel</i>. <b>1</b>: 12–17. Archived from <a href="javascript:if(confirm('http://www.weizmann.ac.il/ICS/booklet/1/pdf/copaxon.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.weizmann.ac.il/ICS/booklet/1/pdf/copaxon.pdf'" tppabs="http://www.weizmann.ac.il/ICS/booklet/1/pdf/copaxon.pdf" class="external text external">the original</a> <span class="cs1-format">(PDF)</span> on 2003-09-07.</cite></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa88f583-4f5f-433b-80b4-1f4c9fb28357  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa88f583-4f5f-433b-80b4-1f4c9fb28357'" tppabs="http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa88f583-4f5f-433b-80b4-1f4c9fb28357" class="external text external">"Copaxone (glatiramer acetate) injection, solution"</a>. DailyMed.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.mult-sclerosis.org/Copaxone.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.mult-sclerosis.org/Copaxone.html'" tppabs="http://www.mult-sclerosis.org/Copaxone.html" class="external text external">"Copaxone"</a>. <i>All About Multiple Sclerosis</i>.</cite></span></li><li id="cite_note-12"> <span id="mw-reference-text-cite_note-12" class="mw-reference-text"><cite id="CITEREFBornsteinMillerSlagleWeitzman1987" class="citation journal cs1">Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, Keilson M, Merriam A, Wassertheil-Smoller S, Spada V (August 1987). "A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis". <i>The New England Journal of Medicine</i>. <b>317</b> (7): 408–14. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJM198708133170703  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJM198708133170703'" tppabs="https://doi.org/10.1056%2FNEJM198708133170703" class="external text external">10.1056/NEJM198708133170703</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/3302705  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/3302705'" tppabs="https://pubmed.ncbi.nlm.nih.gov/3302705" class="external text external">3302705</a>.</cite></span></li><li id="cite_note-13"> <span id="mw-reference-text-cite_note-13" class="mw-reference-text"><cite id="CITEREFJohnsonBrooksCohenFord1995" class="citation journal cs1">Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB (July 1995). "Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group". <i>Neurology</i>. <b>45</b> (7): 1268–76. doi:<a href="javascript:if(confirm('https://doi.org/10.1212%2FWNL.45.7.1268  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1212%2FWNL.45.7.1268'" tppabs="https://doi.org/10.1212%2FWNL.45.7.1268" class="external text external">10.1212/WNL.45.7.1268</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/7617181  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/7617181'" tppabs="https://pubmed.ncbi.nlm.nih.gov/7617181" class="external text external">7617181</a>.</cite></span></li><li id="cite_note-14"> <span id="mw-reference-text-cite_note-14" class="mw-reference-text"><cite id="CITEREFComiFilippiWolinsky2001" class="citation journal cs1">Comi G, Filippi M, Wolinsky JS (March 2001). "European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group". <i>Annals of Neurology</i>. <b>49</b> (3): 290–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1002%2Fana.64  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1002%2Fana.64'" tppabs="https://doi.org/10.1002%2Fana.64" class="external text external">10.1002/ana.64</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/11261502  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/11261502'" tppabs="https://pubmed.ncbi.nlm.nih.gov/11261502" class="external text external">11261502</a>.</cite></span></li><li id="cite_note-15"> <span id="mw-reference-text-cite_note-15" class="mw-reference-text"><cite id="CITEREFMcKeage2015" class="citation journal cs1">McKeage K (May 2015). "Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review". <i>CNS Drugs</i>. <b>29</b> (5): 425–32. doi:<a href="javascript:if(confirm('https://doi.org/10.1007%2Fs40263-015-0245-z  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1007%2Fs40263-015-0245-z'" tppabs="https://doi.org/10.1007%2Fs40263-015-0245-z" class="external text external">10.1007/s40263-015-0245-z</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/25906331  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/25906331'" tppabs="https://pubmed.ncbi.nlm.nih.gov/25906331" class="external text external">25906331</a>.</cite></span></li><li id="cite_note-16"> <span id="mw-reference-text-cite_note-16" class="mw-reference-text"><cite id="CITEREFComiAmatoBertolottoCentonze2016" class="citation journal cs1">Comi G, Amato MP, Bertolotto A, Centonze D, De Stefano N, Farina C,  et al. (2016). <a href="javascript:if(confirm('https://doi.org/10.1186/s40893-016-0010-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1186/s40893-016-0010-2'" tppabs="https://doi.org/10.1186/s40893-016-0010-2" class="external text external">"The heritage of glatiramer acetate and its use in multiple sclerosis"</a>. <i>Multiple Sclerosis and Demyelinating Disorders</i>. <b>1</b> (1). doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1186%2Fs40893-016-0010-2  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1186%2Fs40893-016-0010-2'" tppabs="https://doi.org/10.1186%2Fs40893-016-0010-2" class="external text external">10.1186/s40893-016-0010-2</a></span>.</cite></span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/211/copaxone  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/211/copaxone'" tppabs="http://www.centerwatch.com/drug-information/fda-approved-drugs/drug/211/copaxone" class="external text external">"Copaxone"</a>. <i>CenterWatch</i>.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.thepharmaletter.com/article/teva-s-copaxone-approved-in-uk  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.thepharmaletter.com/article/teva-s-copaxone-approved-in-uk'" tppabs="http://www.thepharmaletter.com/article/teva-s-copaxone-approved-in-uk" class="external text external">"Teva's Copaxone approved in UK"</a>. <i>The Pharma Letter</i>.</cite></span></li><li id="cite_note-19"> <span id="mw-reference-text-cite_note-19" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://tofighdaru.ir/en/products-2/glatiramer-acetate/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://tofighdaru.ir/en/products-2/glatiramer-acetate/'" tppabs="http://tofighdaru.ir/en/products-2/glatiramer-acetate/" class="external text external">"Glatiramer Acetate"</a>. Tofigh Daru Research and Engineering Company.</cite></span></li><li id="cite_note-20"> <span id="mw-reference-text-cite_note-20" class="mw-reference-text"><cite id="CITEREFIsayevJafarov2012" class="citation web cs1">Isayev S, Jafarov T (1 May 2012). <a href="javascript:if(confirm('http://en.trend.az/iran/2020693.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://en.trend.az/iran/2020693.html'" tppabs="http://en.trend.az/iran/2020693.html" class="external text external">"Iran to manufacture multiple sclerosis cure"</a>. <i>Trend News Agency</i>.</cite></span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.novartis.com/news/media-releases/sandoz-announces-us-launch-glatopatm-first-generic-competitor-copaxone%C2%AE-20mg  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.novartis.com/news/media-releases/sandoz-announces-us-launch-glatopatm-first-generic-competitor-copaxone%C2%AE-20mg'" tppabs="https://www.novartis.com/news/media-releases/sandoz-announces-us-launch-glatopatm-first-generic-competitor-copaxone%C2%AE-20mg" class="external text external">"Sandoz announces US launch of Glatopa"</a>. Novartis. 2015.</cite></span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text"><cite id="CITEREFSilva2015" class="citation web cs1">Silva P (9 October 2015). <a href="javascript:if(confirm('https://multiplesclerosisnewstoday.com/2015/10/09/new-3-times-per-week-regimen-tevas-copaxone-safe-effective-increases-patient-compliance-ectrims2015/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://multiplesclerosisnewstoday.com/2015/10/09/new-3-times-per-week-regimen-tevas-copaxone-safe-effective-increases-patient-compliance-ectrims2015/'" tppabs="https://multiplesclerosisnewstoday.com/2015/10/09/new-3-times-per-week-regimen-tevas-copaxone-safe-effective-increases-patient-compliance-ectrims2015/" class="external text external">"New 3-Times-Per-Week Regimen For Teva's Copaxone"</a>. <i>Multiple Sclerosis News Today</i>.</cite></span></li><li id="cite_note-23"> <span id="mw-reference-text-cite_note-23" class="mw-reference-text"><cite id="CITEREFErmanGrover2017" class="citation news cs1">Erman M, Grover D (3 October 2017). <a href="javascript:if(confirm('https://www.reuters.com/article/us-mylan-nl-stocks-teva-pharm-ind/mylan-surges-teva-slumps-after-fda-okays-copaxone-copy-idUSKCN1C91CT  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.reuters.com/article/us-mylan-nl-stocks-teva-pharm-ind/mylan-surges-teva-slumps-after-fda-okays-copaxone-copy-idUSKCN1C91CT'" tppabs="https://www.reuters.com/article/us-mylan-nl-stocks-teva-pharm-ind/mylan-surges-teva-slumps-after-fda-okays-copaxone-copy-idUSKCN1C91CT" class="external text external">"Mylan surges, Teva slumps after FDA okays Copaxone copy"</a>. <i>Reuters</i><span class="reference-accessdate">. Retrieved <span class="nowrap">4 October</span> 2017</span>.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.natcopharma.co.in/about/news  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.natcopharma.co.in/about/news'" tppabs="http://www.natcopharma.co.in/about/news" class="external text external">"NATCO's marketing partner Mylan receives final approval of generic glatiramer acetate, for both 20 mg/mL and 40 mg/mL versions"</a>. <i>NATCO Pharma (India)</i>. 3 October 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">4 October</span> 2017</span>.</cite>&gt;</span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.novartis.com/news/media-releases/sandoz-announces-us-fda-approval-and-launch-glatopar-40-mgml-three-times-week-generic-option-relapsing-forms-multiple-sclerosis  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.novartis.com/news/media-releases/sandoz-announces-us-fda-approval-and-launch-glatopar-40-mgml-three-times-week-generic-option-relapsing-forms-multiple-sclerosis'" tppabs="https://www.novartis.com/news/media-releases/sandoz-announces-us-fda-approval-and-launch-glatopar-40-mgml-three-times-week-generic-option-relapsing-forms-multiple-sclerosis" class="external text external">"Sandoz announces US FDA approval and launch of Glatopa 40 mg/mL"</a>. <i>Novartis International AG</i>. February 13, 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">May 10,</span> 2018</span>.</cite></span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.biopharmadive.com/news/tevas-copaxone-still-growing-despite-patent-risks/423956/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.biopharmadive.com/news/tevas-copaxone-still-growing-despite-patent-risks/423956/'" tppabs="http://www.biopharmadive.com/news/tevas-copaxone-still-growing-despite-patent-risks/423956/" class="external text external">"Teva's Copaxone still growing despite patent risks"</a>. <i>BioPharmaDive</i>.</cite></span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text"><cite id="CITEREFHelfand" class="citation web cs1">Helfand C. <a href="javascript:if(confirm('http://www.fiercepharma.com/special-report/copaxone  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.fiercepharma.com/special-report/copaxone'" tppabs="http://www.fiercepharma.com/special-report/copaxone" class="external text external">"Copaxone"</a>. <i>FiercePharma</i>.</cite></span></li><li id="cite_note-28"> <span id="mw-reference-text-cite_note-28" class="mw-reference-text"><cite id="CITEREFDecker2016" class="citation web cs1">Decker S (1 September 2016). <a href="javascript:if(confirm('https://www.bloomberg.com/news/articles/2016-09-01/teva-loses-decision-on-validity-of-302-copaxone-patent  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.bloomberg.com/news/articles/2016-09-01/teva-loses-decision-on-validity-of-302-copaxone-patent'" tppabs="https://www.bloomberg.com/news/articles/2016-09-01/teva-loses-decision-on-validity-of-302-copaxone-patent" class="external text external">"Teva loses decision on validity of 302 copaxone patent"</a>. <i>Bloomberg Markets</i>.</cite></span></li><li id="cite_note-29"> <span id="mw-reference-text-cite_note-29" class="mw-reference-text"><cite id="CITEREFDeckerFlanaganBenmeleh2017" class="citation web cs1">Decker S, Flanagan C, Benmeleh Y (30 January 2017). <a href="javascript:if(confirm('https://www.bloomberg.com/news/articles/2017-01-30/teva-loses-ruling-invalidating-patents-on-copaxone-drug  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.bloomberg.com/news/articles/2017-01-30/teva-loses-ruling-invalidating-patents-on-copaxone-drug'" tppabs="https://www.bloomberg.com/news/articles/2017-01-30/teva-loses-ruling-invalidating-patents-on-copaxone-drug" class="external text external">"Teva loses ruling invalidating patents on copaxone drug"</a>. <i>Bloomberg Markets</i>.</cite></span></li><li id="cite_note-30"> <span id="mw-reference-text-cite_note-30" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.newspapers.com/clip/21233509/in_the_region/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.newspapers.com/clip/21233509/in_the_region/'" tppabs="https://www.newspapers.com/clip/21233509/in_the_region/" class="external text external">"Teva loses patent ruling"</a>. Briefcase. <i>The Philadelphia Inquirer</i>. Bloomberg News. September 2, 2017. p.<span>&nbsp;</span>A12<span class="reference-accessdate">. Retrieved <span class="nowrap">June 23,</span> 2018</span> <span>–</span> via Newspapers.com (Publisher Extra).</cite></span></li><li id="cite_note-31"> <span id="mw-reference-text-cite_note-31" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.reuters.com/article/teva-mylan-patent/update-1-us-appeals-court-upholds-ruling-that-canceled-teva-copaxone-patents-idUSL2N1WS0PB  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.reuters.com/article/teva-mylan-patent/update-1-us-appeals-court-upholds-ruling-that-canceled-teva-copaxone-patents-idUSL2N1WS0PB'" tppabs="https://www.reuters.com/article/teva-mylan-patent/update-1-us-appeals-court-upholds-ruling-that-canceled-teva-copaxone-patents-idUSL2N1WS0PB" class="external text external">"U.S. appeals court upholds ruling that canceled Teva Copaxone patents"</a>. <i>Reuters</i>. October 12, 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">October 12,</span> 2018</span>.</cite></span></li><li id="cite_note-32"> <span id="mw-reference-text-cite_note-32" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/17-1575.Opinion.10-12-2018.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/17-1575.Opinion.10-12-2018.pdf'" tppabs="http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/17-1575.Opinion.10-12-2018.pdf" class="external text external">"In Re: Copaxone Consolidated Cases"</a> <span class="cs1-format">(PDF)</span>. <i>United States Court of Appeals for the Federal Circuit</i>. October 12, 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">October 12,</span> 2018</span>.</cite></span></li></ol></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><span class="official-website"><span class="url"><a href="javascript:if(confirm('https://www.copaxone.com/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.copaxone.com/'" tppabs="https://www.copaxone.com/" class="external text external">Official website</a></span></span> of Copaxone</li>
<li><a href="javascript:if(confirm('http://www.copaxone.com/Resources/pdfs/PrescribingInformation.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.copaxone.com/Resources/pdfs/PrescribingInformation.pdf'" tppabs="http://www.copaxone.com/Resources/pdfs/PrescribingInformation.pdf" class="external text external">Copaxone Prescribing Information</a></li>
<li><a href="javascript:if(confirm('http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=837  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=837'" tppabs="http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=837" class="external text external">NIH Daily Med, copaxone (glatiramer acetate)</a></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Multiple_sclerosis_and_other_demyelinating_diseases_of_CNS_(G35–G37,_340–341)" style="padding:3px"><table class="nowraplinks hlist mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Multiple_sclerosis_and_other_demyelinating_diseases_of_CNS_(G35–G37,_340–341)" style="font-size:114%;margin:0 4em">Multiple sclerosis and other demyelinating diseases of CNS (<span class="new">G35–G37</span>, 340–341)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Signs and symptoms</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Ataxia</li>
<li>Dawson's fingers</li>
<li>Depression</li>
<li>Diplopia</li>
<li>Dysarthria</li>
<li>Dysphagia</li>
<li>Fatigue</li>
<li>Incontinence</li>
<li>Neurological fatigue</li>
<li>Nystagmus</li>
<li>Optic neuritis</li>
<li>Pain</li>
<li>Uhthoff's phenomenon</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Diagnosis and evolution following</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Clinically isolated syndrome</li>
<li>Diagnostic criteria for MS</li>
<li>EDSS</li>
<li>McDonald criteria</li>
<li>Oligoclonal bands</li>
<li>Poser criteria</li>
<li>Radiologically isolated syndrome</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Investigation</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Experimental autoimmune encephalomyelitis</li>
<li>Multiple sclerosis drug pipeline</li>
<li>Multiple sclerosis research</li>
<li>Pathophysiology</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Approved treatment</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Alemtuzumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a></li>
<li><a href="javascript:if(confirm('https://ptable.com/wiki/compounds/A/Cladribine  \n\nThis file was not retrieved by Teleport VLX, because it was unavailable, or its retrieval was aborted, or the project was stopped too soon.  \n\nDo you want to open it from the server?'))window.location='https://ptable.com/wiki/compounds/A/Cladribine'" tppabs="https://ptable.com/wiki/compounds/A/Cladribine" title="Cladribine">Cladribine</a></li>
<li><a href="Dimethyl_fumarate.htm" tppabs="https://ptable.com/wiki/compounds/A/Dimethyl_fumarate" title="Dimethyl fumarate">Dimethyl fumarate</a></li>
<li>Fingolimod</li>
<li><a href="Glatiramer_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Glatiramer_acetate" title="Glatiramer acetate">Glatiramer acetate</a></li>
<li><a href="Interferon_beta-1a.htm" tppabs="https://ptable.com/wiki/compounds/A/Interferon_beta-1a" title="Interferon beta-1a">Interferon beta-1a</a></li>
<li><a href="Interferon_beta-1b.htm" tppabs="https://ptable.com/wiki/compounds/A/Interferon_beta-1b" title="Interferon beta-1b">Interferon beta-1b</a></li>
<li><a href="Mitoxantrone.htm" tppabs="https://ptable.com/wiki/compounds/A/Mitoxantrone" title="Mitoxantrone">Mitoxantrone</a></li>
<li>Natalizumab</li>
<li>Ocrelizumab</li>
<li>Ozanimod</li>
<li>Siponimod</li>
<li>Teriflunomide</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Former treatment</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Daclizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Daclizumab" title="Daclizumab">Daclizumab</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Borderline forms</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Acute disseminated encephalomyelitis</li>
<li>AntiMOG associated encephalomyelitis</li>
<li>Balo concentric sclerosis</li>
<li>Marburg multiple sclerosis</li>
<li>Neuromyelitis optica</li>
<li>Oligoclonal negative MS</li>
<li>Schilder's disease</li>
<li>Tumefactive multiple sclerosis</li>
<li>Some autoimmune PNS diseases like Guillain-Barré syndrome and CIDP normally set apart</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>List of multiple sclerosis organizations</li>
<li>List of people with multiple sclerosis</li></ul>
</div></td></tr></tbody></table></div>
<div role="navigation" class="navbox" aria-labelledby="Immunostimulants_(L03)" style="padding:3px"><table class="nowraplinks hlist mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Immunostimulants_(L03)" style="font-size:114%;margin:0 4em">Immunostimulants (L03)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Endogenous</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Cytokines</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Colony-stimulating factors</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>G-CSF
<ul><li><a href="Filgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Filgrastim" title="Filgrastim">Filgrastim</a> / Lipegfilgrastim / <a href="Pegfilgrastim.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegfilgrastim" title="Pegfilgrastim">Pegfilgrastim</a></li>
<li>Lenograstim</li>
<li><i>Eflapegrastim</i></li></ul></li>
<li>GM-CSF
<ul><li>Molgramostim</li>
<li><a href="Sargramostim.htm" tppabs="https://ptable.com/wiki/compounds/A/Sargramostim" title="Sargramostim">Sargramostim</a></li></ul></li>
<li>SCF
<ul><li>Ancestim</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Interferons</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>alpha</i>:
<ul><li>Albinterferon</li>
<li>Interferon alfa natural</li>
<li><span class="new">Interferon alfa 2a</span> / Peginterferon alfa-2a</li>
<li>Interferon alfa 2b / Peginterferon alfa-2b</li>
<li><span class="new">Interferon alfa n1</span></li>
<li><a href="Interferon_alfacon-1.htm" tppabs="https://ptable.com/wiki/compounds/A/Interferon_alfacon-1" title="Interferon alfacon-1">Interferon alfacon-1</a></li>
<li>Interferon alpha-n3</li></ul></li>
<li><i>beta</i>:
<ul><li>Interferon beta natural</li>
<li>Interferon beta 1a</li>
<li>Interferon beta 1b</li></ul></li>
<li>Interferon gamma</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Interleukins</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">Aldesleukin</a></li>
<li><a href="Oprelvekin.htm" tppabs="https://ptable.com/wiki/compounds/A/Oprelvekin" title="Oprelvekin">Oprelvekin</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other protein / peptide</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Growth_hormone.htm" tppabs="https://ptable.com/wiki/compounds/A/Growth_hormone" title="Growth hormone">Growth hormone</a></li>
<li>Immunocyanin</li>
<li><a href="Adenosine_deaminase.htm" tppabs="https://ptable.com/wiki/compounds/A/Pegademase" title="Pegademase" class="mw-redirect">Pegademase</a></li>
<li>Prolactin</li>
<li>Tasonermin</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Female sex steroids</li>
<li><a href="Histamine_dihydrochloride.htm" tppabs="https://ptable.com/wiki/compounds/A/Histamine_dihydrochloride" title="Histamine dihydrochloride">Histamine dihydrochloride</a></li>
<li>Poly ICLC</li>
<li><a href="Vitamin_D.htm" tppabs="https://ptable.com/wiki/compounds/A/Vitamin_D" title="Vitamin D">Vitamin D</a></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Exogenous</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>beta-glucan
<ul><li>Lentinan</li></ul></li>
<li>heterocyclic compound
<ul><li>Plerixafor</li></ul></li>
<li><a href="8-Hydroxyquinoline.htm" tppabs="https://ptable.com/wiki/compounds/A/8-Hydroxyquinoline" title="8-Hydroxyquinoline">hydroxyquinoline</a>
<ul><li>Roquinimex</li></ul></li>
<li>Mifamurtide</li>
<li>oligopeptides
<ul><li><a href="Glatiramer_acetate.htm" tppabs="https://ptable.com/wiki/compounds/A/Glatiramer_acetate" title="Glatiramer acetate">Glatiramer acetate</a></li>
<li>Thymopentin</li>
<li>Thymosin α1</li>
<li>Thymulin</li></ul></li>
<li>polyribonucleotide
<ul><li>Polyinosinic:polycytidylic acid</li></ul></li>
<li><a href="Thiazolidine.htm" tppabs="https://ptable.com/wiki/compounds/A/Thiazolidine" title="Thiazolidine">thiazolidine</a>
<ul><li><a href="Pidotimod.htm" tppabs="https://ptable.com/wiki/compounds/A/Pidotimod" title="Pidotimod">Pidotimod</a></li></ul></li>
<li>vaccines
<ul><li>Bacillus Calmette–Guérin</li>
<li>Melanoma vaccine</li>
<li>Sipuleucel-T</li></ul></li></ul>
</div></td></tr></tbody></table></div>

<meta property="mw:PageProp/categorydefaultsort" content="Glatiramer Acetate">


<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details><!--htdig_noindex--><div><div style="clear:both; background-image:linear-gradient(180deg, #E8E8E8, white); border-top: dashed 2px #AAAAAA; padding: 0.5em 0.5em 0.5em 0.5em; margin-top: 1em; direction: ltr;">
    This article is issued from <a class="external text" title="Last edited on 2020-06-22" href="javascript:if(confirm('https://en.wikipedia.org/wiki/?title=Glatiramer_acetate&oldid=963844564  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/wiki/?title=Glatiramer_acetate&oldid=963844564'" tppabs="https://en.wikipedia.org/wiki/?title=Glatiramer_acetate&oldid=963844564">Wikipedia</a>. The text is licensed under <a class="external text" href="javascript:if(confirm('https://creativecommons.org/licenses/by-sa/4.0/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://creativecommons.org/licenses/by-sa/4.0/'" tppabs="https://creativecommons.org/licenses/by-sa/4.0/">Creative Commons - Attribution - Sharealike</a>. Additional terms may apply for the media files.
</div>
</div><!--/htdig_noindex--></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>